Revisiting amoxicillin prophylaxis for infective endocarditis: a pharmacokinetic and cost-effectiveness analysis
Authors:
- Oisín KavanaghOKOisín Kavanagh
- David EdwardsDEDavid Edwards
- Beker KhalidBKBeker Khalid
Preprint
- 25 September 2026
- preprint
- Published by Springer Nature in Research Square
Abstract
Introduction The role of antibiotic prophylaxis in preventing infective endocarditis has long been contentious, and recent changes to United Kingdom guidance now recommend prophylaxis for patients at high risk undergoing invasive dental procedures. Comparatively little attention has been directed towards optimisation of the prophylactic amoxicillin regimen itself. This study evaluated the pharmacokinetic and economic rationale underpinning contemporary dental amoxicillin prophylaxis. Methods National Health Service dental prescribing data and Drug Tariff pricing information were analysed to characterise amoxicillin prescribing patterns and costs. Published pharmacokinetic studies were reviewed to examine the relationship between amoxicillin dose, bioavailability, and systemic exposure. A model was developed to compare exposure achieved by conventional prophylactic regimens and alternative divided-dose strategies. A previously published cost-effectiveness model was rebuilt as a cost-utility analysis using contemporary amoxicillin pricing, pooled efficacy estimates from a recent meta-analysis, and updated estimates of infective endocarditis incidence following invasive dental procedures. Incremental costs, quality-adjusted life years (QALYs) and threshold acquisition costs were calculated, with deterministic and probabilistic sensitivity analyses. Results Amoxicillin remained one of the most prescribed antibiotics in dentistry, accounting for approximately 40% of dental prescribing. Published pharmacokinetic studies demonstrated dose-dependent absorption, with bioavailability declining at higher oral doses. Simulations showed that repeated 500 mg doses administered every 6 hours achieved comparable pharmacodynamic target attainment to conventional 3 g prophylactic regimens despite substantially lower individual doses. The cost of 3 g amoxicillin sachets increased markedly over the study period, producing an approximately 57-fold to 114-fold difference in the cost of a prophylactic course compared with 500 mg capsules, depending on whether a single sachet or a dispensed pack of two was costed. Cost-utility analysis indicated that prophylaxis remained cost-effective in high-risk patients under every costing and formulation examined, with an incremental cost-effectiveness ratio of £140 per QALY for the 3 g sachet and dominance for capsule-based regimens in every group examined. Conclusions Current high-dose amoxicillin prophylaxis regimens may be pharmacokinetically inefficient because of dose-dependent absorption. Lower-dose divided regimens achieved comparable simulated pharmacodynamic exposure at substantially lower cost. Formulation choice, rather than dose, determined whether prophylaxis remained cost-saving. Prospective clinical studies are required to determine whether the pharmacokinetic advantages of lower-dose regimens translate into improved clinical outcomes.Keywords
All Related Versions
This publication has 27 references indexed in Scilit:
- Infective Endocarditis Risk After Invasive Dental ProceduresMayo Clinic Proceedings: Innovations, Quality & Outcomes, 2025
- Endocarditis Prophylaxis—Indications, Application and Current ControversiesCanadian Journal of Cardiology, 2025
- Antibiotic Prophylaxis and Infective Endocarditis Incidence Following Invasive Dental ProceduresJAMA Cardiology, 2024
- Endocarditis prevention: time for a review of NICE guidanceThe Lancet Regional Health - Europe, 2024
- Amoxicillin therapeutic drug monitoring for endocarditis: A comparative study (EI-STAB)International Journal of Antimicrobial Agents, 2023
- Trends in antibiotic prescribing by dental practitioners in GermanyJournal of Cranio-Maxillofacial Surgery, 2017
- An evaluation of dental antibiotic prescribing practices in the United StatesThe Journal of the American Dental Association, 2017
- Nonlinearity of amoxicillin absorption kinetics in humanEuropean Journal of Clinical Pharmacology, 1992
- Pharmacology of ticarcillin combined with clavulanic acid in humansThe American Journal of Medicine, 1985
- Comparative pharmacokinetic analysis of amoxycillin using open two and three-compartment modelsEuropean Journal of Clinical Pharmacology, 1982